Objectives: This analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates pooled from the adult Phase III clinical trials in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP).
Introduction
Complicated intra-abdominal infections (cIAIs), complicated urinary tract infections (cUTIs) and nosocomial pneumonia (NP) are commonly associated with Enterobacteriaceae and Pseudomonas aeruginosa. [1] [2] [3] The increasing prevalence and diversity of antimicrobial resistance mechanisms, in particular ESBLs, has driven an increase in first-line use of carbapenems for infections that would previously have been treated with cephalosporins, which is in turn contributing to a rising incidence of pathogens harbouring carbapenemases and further limiting treatment options. certain MDR pathogens. 5, 6 The combination is approved in the USA and Europe for the treatment of serious infections due to Gram-negative bacteria 7, 8 and has completed Phase III trials in adult patients with cIAI (RECLAIM 1 and 2, NCT01499290; RECLAIM 3, NCT01726023), 9 ,10 cUTI (RECAPTURE 1 and 2, NCT01595438 and NCT01599806), 11 NP including ventilator-associated pneumonia (VAP; REPROVE, NCT01808092) 12 and cUTI or cIAI caused by ceftazidime-non-susceptible pathogens (REPRISE, NCT01644643). 13 This post hoc exploratory analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and P. aeruginosa isolates 14 pooled from the ceftazidime/avibactam Phase III clinical trials.
Patients and methods

Study design
Baseline isolate and microbiological and clinical response data were pooled from five ceftazidime/avibactam adult Phase III trials (summarized in Table S1 , available as Supplementary data at JAC Online). [9] [10] [11] [12] [13] These analyses used data from the microbiologically modified ITT (mMITT) populations, defined variously by study (Table S2 ), but generally including all patients with confirmed presence of relevant infection and at least one studyqualifying Gram-negative pathogen. [9] [10] [11] [12] [13] In each trial, patients with Cockcroft-Gault-estimated creatinine clearance .50 mL/min were randomized to receive either 2000/500 mg of ceftazidime/avibactam by 2 h intravenous (iv) infusion every 8 h (plus metronidazole in patients with cIAI) or a comparator drug [carbapenems in all trials, except in the REPRISE trial, in which a carbapenem-based best available therapy was administered to most patients (Table S1) ]. Treatment duration varied from 5 to 21 days between trials (Table S1 ).
Pathogen characterization
Specimens for bacterial culture obtained from patients during each trial included samples from abdominal infection sites, blood, urine or the respiratory tract. [9] [10] [11] [12] [13] Isolates were characterized by local laboratories. A central laboratory (Covance Central Laboratory Services, Indianapolis, IN, USA) confirmed identification and performed susceptibility testing using CLSI broth microdilution methodology. 15, 16 Susceptibility data were interpreted according to CLSI MIC breakpoints. 16 MDR for Enterobacteriaceae and P. aeruginosa was defined as resistance to 3 of the respective antimicrobial classes, accounting for noted exemptions (Table S3). 14 Comparator susceptibility data have been reported previously. [9] [10] [11] [12] [13] As different comparators were used across the clinical trials, pooled comparator susceptibility analyses were not conducted for the MDR clinical trial isolates.
Study measures
Endpoints in each trial included clinical and microbiological responses assessed at the test-of-cure (TOC) visit. Timing of the TOC visit (Table S1 ) and the definitions of microbiological and clinical response varied by study (Tables S4 and S5 ). [9] [10] [11] [12] [13] In general, a favourable per-pathogen microbiological response was microbiologically confirmed eradication or presumed eradication of the baseline pathogen and clinical cure was investigatorassessed resolution of signs and symptoms of the baseline infection without need for further antibiotics. Per-pathogen favourable microbiological response rates and clinical cure rates at TOC in the mMITT population were pooled for ceftazidime/avibactam and comparators for this analysis of MDR pathogens.
Statistical methods
All analyses were performed using SAS V R software Version 9.1 or higher (SAS Institute, Inc., Cary, NC, USA).
Results
Patients
The pooled mMITT population included 2585 patients from countries across North and South America, Europe, Asia and Africa.
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Baseline pathogens and susceptibility profiles
In the pooled dataset, 1051 of 2240 (46.9%) patients with Enterobacteriaceae and 95 of 272 (34.9%) patients with P. aeruginosa had MDR pathogens (Table S6 ). The numbers of patients with MDR pathogens were similar in the ceftazidime/ avibactam and comparator groups ( Stone et al.
Microbiological responses
The proportions of patients with favourable microbiological responses at TOC were similar for ceftazidime/avibactam and comparators [78.4% versus 71.6% for all Enterobacteriaceae and 57.1% versus 53.8% for P. aeruginosa (Table 2) ]. Similar favourable microbiological response rates were generally observed across all indications for all Enterobacteriaceae isolates and for P. aeruginosa, although the rates for P. aeruginosa were lower in both treatment arms for the NP/VAP cohort than for other indications (Table 2) . 
Clinical responses
Discussion
This analysis demonstrates that MDR isolates were present in the ceftazidime/avibactam Phase III trials with a similar distribution between trials and across treatment arms. The numbers of patients with MDR pathogens reported here may slightly underestimate the true distribution, because not all isolates from the trials were sent to the central laboratory. Nevertheless, the microbiological and clinical responses with respect to the MDR pathogens described here were consistent with the overall results in each trial, which were not analysed by MDR status. [9] [10] [11] [12] [13] Numerical variations in the responses across each set of pathogens analysed should be interpreted with caution owing to the small numbers of isolates in some of the groups. The majority of patients with MDR Enterobacteriaceae infections demonstrated favourable microbiological responses to ceftazidime/avibactam and comparators. This is consistent with the ceftazidime/avibactam MIC 90 for all MDR Enterobacteriaceae (1 mg/L) being below the susceptibility breakpoint of 8 mg/L. Similar susceptibility data have been reported for ceftazidime/avibactam among MDR Enterobacteriaceae from global surveillance studies. 17 Within the MDR Enterobacteriaceae, some species demonstrated reduced susceptibility to ceftazidime/avibactam. The MIC 90 value for MDR E. cloacae (32 mg/L; 89.7% susceptible) was above the susceptibility breakpoint for ceftazidime/avibactam and, across indications, favourable microbiological response rates for patients with MDR E. cloacae were lower for ceftazidime/avibactam (69.0%) than comparators (82.8%). However, data from a global antimicrobial surveillance programme reported a ceftazidime/avibactam MIC 90 value for 1198 E. cloacae isolates of 0.5-1 mg/L, 18 suggesting that our result may be atypical and possibly reflects the low number of isolates obtained.
The MIC 90 value of ceftazidime/avibactam for MDR P. aeruginosa isolates (64 mg/L) also exceeded the susceptible breakpoint (8 mg/L) and 66.1% of isolates were susceptible to Ceftazidime/avibactam against MDR bacteria JAC ceftazidime/avibactam. Favourable microbiological response rates were similar in both arms of the study (57.1% and 53.8%, respectively) and numerically lower than those observed among Enterobacteriaceae. Higher susceptibility rates to ceftazidime/avibactam were reported for P. aeruginosa isolates in global surveillance studies. 17, 19 It is plausible that the clinical results may have been affected by the production of class B MBLs and class D b-lactamase (other than OXA-48) in P. aeruginosa isolates, against which avibactam has no inhibitory effect. 20 The results should be interpreted with caution owing to the small number of P. aeruginosa isolates.
Similar proportions of patients with 1 MDR pathogen were clinically cured at TOC in the ceftazidime/avibactam and comparator arms. Clinical cure rates were slightly lower in the NP/VAP cohort across both treatment arms, perhaps reflecting a more severely ill patient population.
The definitions of clinical and microbiological response varied slightly across the studies (Tables S4 and S5 ), which should be considered in the interpretation of this analysis. In addition, the definition of MDR was one that is broadly accepted and was based on that published by Magiorakos et al., 14 comprising resistance to at least one agent in 3 antimicrobial classes. We accounted for intrinsic resistance to ampicillin in noted species 14 and limiting ceftaroline non-susceptibility in Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. However, a definition that excludes penicillin and ampicillin, and in which ceftaroline is included in the same class as ceftriaxone and ceftazidime, might better reflect the true nature of an MDR pathogen that has acquired resistance to 3 antimicrobial classes. This dataset also does not account for either the development of resistance to ceftazidime/avibactam during the Phase III trials or emergent infections. Across the trials, a few cases were reported of persistent infection with increasing MIC of ceftazidime/avibactam, but only one case of resistance developing to ceftazidime/avibactam, and the numbers of emergent events were low. [9] [10] [11] [12] [13] In conclusion, the ceftazidime/avibactam Phase III clinical trial programme successfully demonstrated ceftazidime/avibactam to be a suitable alternative to carbapenem-based therapies for certain serious Gram-negative infections. The present analysis of MDR Enterobacteriaceae and P. aeruginosa clinical trial isolates demonstrates the similar clinical activity of ceftazidime/avibactam compared with predominantly carbapenem-based comparators against this clinically important group of pathogens.
